Lisanne P Zijlker, Henry Chen, Andrew J Spillane, Maria Gonzalez, Thomas E Pennington, Alexander M Menzies, Serigne N Lo, Peter Ferguson, Robert Rawson, Andrew J Colebatch, Jonathan R Stretch, John F Thompson, Sydney Ch'ng, Omgo Nieweg, Kerwin F Shannon, Georgina V Long, Richard A Scolyer, Robyn P M Saw, Alexander C J van Akkooi
BACKGROUND: Neoadjuvant systemic therapy (NAST) for patients with stage III melanoma achieves high major pathologic response rates and high recurrence-free survival rates. This study aimed to determine how NAST with targeted therapies (TTs) and immune checkpoint inhibitors (ICIs) influences surgical outcomes after lymph node dissection in terms of complications, morbidity, and textbook outcomes. METHODS: Patients who underwent a lymph node dissection after either NAST in a clinical trial or upfront surgery for stage III melanoma between 2014 and 2022 were identified from an institutional research database...
May 18, 2024: Annals of Surgical Oncology